Haemonetics Corporation HAE delivered fourth-quarter fiscal 2025 adjusted earnings per share (EPS) of $1.24, which rose 37.8% ...

Venous thromboembolism (VTE), comprising deep vein thrombosis and pulmonary embolism, is a major cause of morbidity and ...

April's clearances included respiratory disease assays, a Gram-negative infection test, and assays to aid the diagnosis and monitoring of thyroid disease.

The global hemostatic gels market, valued at USD 1.0 billion in 2022, is set to experience significant growth, projected to reach USD 1.9 billion by 2032, expanding at a compound annual growth rate ...

The risk of someone younger than 40 having a VTE is about 1 in 10,000, said Dr. Mary Cushman, a hematologist who is medical director of the Thrombosis and Hemostasis Program at the University of ...

The facility combines five laboratory disciplines—clinical chemistry, immunoassay, serology, hematology, and hemostasis—into ...

US-based medical device technology company HemoSonics has won the Marketing award in the 2025 Medical Device Network ...

The REVERSE-IT trial showed bentracimab effectively reversed the effects of ticagrelor, restoring platelet function with ...

The investment will support the company's core areas of bioelectronic medicine, including neurological health, hemostasis, ...

HemoSonics Wins 2025 Medical Device Network Excellence Award for the Impactful Marketing of Its Quantra Hemostasis System ...